Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gefitinib in Stage I NSCLC
NCT00188617Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jan 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by University Health Network. Primary endpoints: Pathologic Response Rate at 28 days and Radiological Response Rate at 28 days. Started Jan 2005; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00188617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00188617.